It didn’t take long for shares of International Business Machines (NYSE:IBM) to return to their winning ways. With a video clip from President Trump referring to CEO Arvind Krishna as a “legend” resurfacing online in viral fashion, questions linger as to what’s up with the sudden awakening of a name that was seemingly left behind ... IBM Set Records, Delivered 44% Gains in a Single Month as Trump ...
It didn’t take long for shares of International Business Machines (NYSE:IBM) to return to their winning ways. With a video clip from President Trump referring to CEO Arvind Krishna as a “legend” resurfacing online in viral fashion, questions linger as to what’s up with the sudden awakening of a name that was seemingly left behind ... IBM Set Records, Delivered 44% Gains in a Single Month as Trump Clip Resurfaces
Canadian Imperial Bank of Commerce ( TSX: CM ) on Thursday said it had received Toronto Stock Exchange approval for a new normal course issuer bid allowing it to repurchase and cancel up to 30 million common shares. The buyback represents about 3.3% of CIBC's 912.8 million issued and outstanding common shares as of May 31, 2026. Repurchases may begin on June 8 and continue until June 7, 2027, unle...
Canadian Imperial Bank of Commerce ( TSX: CM ) on Thursday said it had received Toronto Stock Exchange approval for a new normal course issuer bid allowing it to repurchase and cancel up to 30 million common shares. The buyback represents about 3.3% of CIBC's 912.8 million issued and outstanding common shares as of May 31, 2026. Repurchases may begin on June 8 and continue until June 7, 2027, unless completed earlier or terminated by the bank. CIBC said it had completed its previous share repurchase program, buying back and cancelling 20 million common shares at an average price of $129.68 per share for a total of about $2.6 billion. The bank said purchases under the new program may be made through the Toronto Stock Exchange, alternative Canadian trading systems, and the New York Stock Exchange. Shares acquired under the program will be cancelled. CIBC also said it had entered into an automatic share purchase plan with CIBC Capital Markets, which allows share repurchases during periods when the bank would otherwise be restricted from trading under insider trading rules or internal blackout policies. Source: Press Release More on Canadian Imperial Bank of Commerce Scotiabank upgrades Bank of Montreal, downgrades Canadian Imperial Bank of Commerce after FQ2 earnings CIBC Q2 earnings top consensus on robust capital markets, wealth management performance
mtcurado/iStock Unreleased via Getty Images After sitting for a few months with a 'Buy' rating on Village Super Market ( VLGEA ), I came up with a take-profits idea for the $40s. It wasn't anything too complicated. Seeking Alpha In April, Village was trading right at its fair value and, with a weak dividend yield for grocery stock (~2%) and without a consistent buyback plan, it didn't make sense t...
mtcurado/iStock Unreleased via Getty Images After sitting for a few months with a 'Buy' rating on Village Super Market ( VLGEA ), I came up with a take-profits idea for the $40s. It wasn't anything too complicated. Seeking Alpha In April, Village was trading right at its fair value and, with a weak dividend yield for grocery stock (~2%) and without a consistent buyback plan, it didn't make sense to hold it at that moment. Hard-discounters could eat up some of the market share (and, as we'll see shortly, they did) and soon the stock would become slightly undervalued again. My thesis just needed a catalyst. And it seems that Q3 FY 2026 (which ended in early June of this year) was enough. Post-earnings, the stock fell almost 20% to ~$37. Today it's rising again, but it's still at least ~10% away from my last 'Sell' rating. Is it time to fish for the bottom again? Right off the bat, you can say no. Based on the valuation, from here to the low-$40s offers an upside of at least a low-single digit. I wouldn't say it's worth buying precisely because the total return would be something very close to 5%, and I'm being quite generous here. But I think it's worth not overlooking these earnings . If you look at Weis Markets ( WMK )—a peer in the Mid-Atlantic—you'll notice that the market digested the reports differently. Storm Fern Wasn't the Only One to Blame Even if you don't follow Village or even the grocery segment, three things stand out in these results . The first is that same-store sales not only fell, but slowed down significantly compared to Q2 FY 2026. They were -0.2% (compared to ~1.2% for Weis), a dip of 500 bp compared to the last quarter. But there's a catch: Storm Fern. In the last quarter, people filled their carts more in anticipation of it. So, if you look at same-store sales disregarding that, they would have risen 1.4%. And, since the dip in Q3 FY 2026 was also due to Fern, normalizing it would have shown a growth of 1.3%. A slowdown of only ~10 bp. Here's ...
Deliveries in 30 minutes or less coming to Manchester and Birmingham and fresh groceries service to start in London Amazon is expanding fast-track deliveries in the UK, including adding fresh fruit and vegetables to same-day services, after closing its standalone grocery stores . The firm said it would expand Amazon Now, its ultra-fast delivery service that already delivers goods in less than 30 m...
Deliveries in 30 minutes or less coming to Manchester and Birmingham and fresh groceries service to start in London Amazon is expanding fast-track deliveries in the UK, including adding fresh fruit and vegetables to same-day services, after closing its standalone grocery stores . The firm said it would expand Amazon Now, its ultra-fast delivery service that already delivers goods in less than 30 minutes to parts of London, to also serve Manchester and Birmingham this year. Continue reading...
Ares Management's ( ARES ) co-president, Blair Jacobson, said in an interview with Bloomberg TV that there's a "real disconnect" between media headlines over private credit and what the company is seeing across its portfolio companies. Jacobson said Ares' 3,000 or so companies are growing at between 8% and 12% a year, according to the Bloomberg report published on Thursday. Rates of non-accrual ar...
Ares Management's ( ARES ) co-president, Blair Jacobson, said in an interview with Bloomberg TV that there's a "real disconnect" between media headlines over private credit and what the company is seeing across its portfolio companies. Jacobson said Ares' 3,000 or so companies are growing at between 8% and 12% a year, according to the Bloomberg report published on Thursday. Rates of non-accrual are lower than what the company has seen historically, and the broader macroeconomic picture is supportive, Jacobson reportedly said. Furthermore, the capital flow reduction into the industry, fueled by retail investors' increased caution, benefits the asset class in some ways, according to the co-president. Ares' portfolio companies are in a "mathematically comfortable" position with no signs of major distress in the liquid market for loans and bonds, Jacobson reportedly said. Downplaying concerns about private credit managers curbing redemptions, he said, "The underlying funds are meeting what we guide investors to expect from high single-digit, double-digit returns." The news comes after Cliffwater was said to have curbed redemptions at its private credit fund for the second quarter as well, raising fresh doubts over the health of the private credit industry ( VPC ) ( BIZD ) ( PRIV ) . More on Ares Management Corporation Ares Management Corporation (ARES) Presents at Goldman Sachs 30th Annual European Financials Conference 2026 Transcript Ares Management: Bonds Might Still Offer The Best Deal Ares Management Corporation (ARES) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript Private credit names decline as Cliffwater's Q2 redemption requests cast fresh doubts on industry health Ares' M&A activities have been better than hoped - CEO
Futures Slide After Broadcom Forecast Miss Chills Tech Euphoria US equity futures are weaker, dragged lower by Tech after a disappointing outlook from Broadcom triggered doubts that the blistering rally in technology shares had gone too far, a move exacerbated by euphoric positioning. As of 8:00am ET, S&P futures dropped 0.4%, while Nasdaq futures slumped 1.2%. Broadcom, which added around $150 bi...
Futures Slide After Broadcom Forecast Miss Chills Tech Euphoria US equity futures are weaker, dragged lower by Tech after a disappointing outlook from Broadcom triggered doubts that the blistering rally in technology shares had gone too far, a move exacerbated by euphoric positioning. As of 8:00am ET, S&P futures dropped 0.4%, while Nasdaq futures slumped 1.2%. Broadcom, which added around $150 billion in market value just this week, slumped 13% in US premarket trading after its forecast for artificial-intelligence semiconductor revenue in the current quarter fell short of expectations. CrowdStrike shares also drop 10% after their revenue projection failed to impress investors. Semis are under pressure following AVGO’s earnings, while Mag7 are bid led by AAPL (+1%). Parts of Cyclicals and Defensives are bid as portions of the AI Theme are weaker pointing to a potential de-risking or the very early stages a rotation. Given the sell off in APAC and EU bid, it appears to be the former rather than the latter. Bond yields are lower as the curve bull steepens, and USD weakens. Commodities are lower as Energy sells-off on news that Israel / Lebanon will resume their conditional ceasefire within 24 hours (although Hezbollah was notably not mentioned); but, precious metals are a notable outperformer. Today’s macro data focus is on Challenge Job Cuts, Initial Claims, and Continuing Claims, with NFP coming tomorrow. In premarket trading, Mag 7 stocks are mixed (Microsoft +0.8%, Amazon +1.1%, Apple +1%, Alphabet +0.4%, Nvidia -1%, Meta Platforms -0.7%, Tesla -0.8%. Broadcom (AVGO) is down 14% after the chipmaker gave an outlook that was seen as underwhelming, given the industry’s AI-related demand. Analysts note that AI sales and margins for the current quarter are weaker than expected. AI-linked companies fall after Broadcom’s outlook for AI chip revenue failed to impress investors. Decliners include Intel (INTC), which is down about 4%, and Lumentum (LITE), which is falling 3...
JHVEPhoto Broadcom ( AVGO ) was in focus on Thursday after the semiconductor and software company reported second-quarter results and guidance. And while investors may be concerned Broadcom did not lift its outlook for artificial intelligence-related sales for the rest of the year, Wall Street still sees a bright future for the Hock Tan-led company. Shares fell 15% in premarket trading, dragging d...
JHVEPhoto Broadcom ( AVGO ) was in focus on Thursday after the semiconductor and software company reported second-quarter results and guidance. And while investors may be concerned Broadcom did not lift its outlook for artificial intelligence-related sales for the rest of the year, Wall Street still sees a bright future for the Hock Tan-led company. Shares fell 15% in premarket trading, dragging down other chipmakers, such as Intel ( INTC ), Nvidia ( NVDA ), and AMD ( AMD ). Bernstein analyst Stacy Rasgon pointed out that AI revenue can be “lumpy,” but given that they're expected to be up 200% year-over-year in the coming quarter and $100B next year, it's impressive nonetheless. “While 2027 appears 2H-weighted as multiple programs ramp, this also suggesting a potentially materially higher run-rate into 2028, accompanied by stronger baseline growth from the non-AI businesses (SW, other semis) in the meantime,” Rasgon wrote in a note to clients. “And while we get the complaints on (slightly) declining gross margins as AI ASICs ramp, operating leverage is clearly offsetting (and we feel bad complaining about gross margins that remain well into the 70s anyway...) We suspect the shares may take a pause for the next couple of quarters. But the story gets interesting again once we enter 2027. And at the end of the day, we have a company growing revenues and EPS >50%, with gross/operating margins in the 70s/60s, and potentially trading at a teens P/FE in an environment that is only getting stronger. If we have to wait a quarter or two for that story to re-emerge that’s OK, we’ll wait for it.” Rasgon reiterated his Outperform rating on Broadcom and raised his price target to $550 from $525. Goldman Sachs analyst James Schneider said he would be “aggressive buyers” of the stock for several reasons, given the sharp reaction to the results and guidance. “We remain bullish on the stock at current levels as our confidence on Broadcom’s growth in 2027 and beyond is underpinned by ...
JHVEPhoto Broadcom ( AVGO ) was in focus on Thursday after the semiconductor and software company reported second-quarter results and guidance. And while investors may be concerned Broadcom did not lift its outlook for artificial intelligence-related sales for the rest of the year, Wall Street still sees a bright future for the Hock Tan-led company. Shares fell 15% in premarket trading, dragging d...
JHVEPhoto Broadcom ( AVGO ) was in focus on Thursday after the semiconductor and software company reported second-quarter results and guidance. And while investors may be concerned Broadcom did not lift its outlook for artificial intelligence-related sales for the rest of the year, Wall Street still sees a bright future for the Hock Tan-led company. Shares fell 15% in premarket trading, dragging down other chipmakers, such as Intel ( INTC ), Nvidia ( NVDA ), and AMD ( AMD ). Bernstein analyst Stacy Rasgon pointed out that AI revenue can be “lumpy,” but given that they're expected to be up 200% year-over-year in the coming quarter and $100B next year, it's impressive nonetheless. “While 2027 appears 2H-weighted as multiple programs ramp, this also suggesting a potentially materially higher run-rate into 2028, accompanied by stronger baseline growth from the non-AI businesses (SW, other semis) in the meantime,” Rasgon wrote in a note to clients. “And while we get the complaints on (slightly) declining gross margins as AI ASICs ramp, operating leverage is clearly offsetting (and we feel bad complaining about gross margins that remain well into the 70s anyway...) We suspect the shares may take a pause for the next couple of quarters. But the story gets interesting again once we enter 2027. And at the end of the day, we have a company growing revenues and EPS >50%, with gross/operating margins in the 70s/60s, and potentially trading at a teens P/FE in an environment that is only getting stronger. If we have to wait a quarter or two for that story to re-emerge that’s OK, we’ll wait for it.” Rasgon reiterated his Outperform rating on Broadcom and raised his price target to $550 from $525. Goldman Sachs analyst James Schneider said he would be “aggressive buyers” of the stock for several reasons, given the sharp reaction to the results and guidance. “We remain bullish on the stock at current levels as our confidence on Broadcom’s growth in 2027 and beyond is underpinned by ...
Exclusive: New loopholes for developers will exacerbate extreme environmental disparities, charity coalition warns The poorest and most nature-deprived communities in England will be further left behind in their access to green spaces if proposed changes to planning laws go ahead, a report finds. More than 7.4 million people in England live in areas completely devoid of immediate biodiversity, inc...
Exclusive: New loopholes for developers will exacerbate extreme environmental disparities, charity coalition warns The poorest and most nature-deprived communities in England will be further left behind in their access to green spaces if proposed changes to planning laws go ahead, a report finds. More than 7.4 million people in England live in areas completely devoid of immediate biodiversity, including 1.42 million children under 15, the report commissioned by a number of wildlife and environmental NGOs says. Continue reading...
Trevor Williams/DigitalVision via Getty Images From biotech to orbital infrastructure, the 2026 technology story is being written across industries. Five VanEck ETFs offer targeted exposure to each distinct theme. The Tech Landscape in 2026: What Has Changed Technology is no longer just a software story. As AI moves deeper into the economy, the companies enabling it now span semiconductors, roboti...
Trevor Williams/DigitalVision via Getty Images From biotech to orbital infrastructure, the 2026 technology story is being written across industries. Five VanEck ETFs offer targeted exposure to each distinct theme. The Tech Landscape in 2026: What Has Changed Technology is no longer just a software story. As AI moves deeper into the economy, the companies enabling it now span semiconductors, robotics, electrification, gaming, space and biotech. Compute capacity depends on chips and advanced manufacturing, automation relies on sensors and industrial control systems, and space infrastructure is becoming a new layer for communications and data. The 2026 technology landscape is not being shaped by one company or subsector. Innovation is spreading across the industries and systems that support the next phase of growth. Five Tech Companies to Watch Across VanEck ETFs Tech Theme VanEck ETF Featured Company What It Represents Biotechnology VanEck Biotech ETF ( BBH ) Gilead Sciences Therapies across virology, oncology and precision medicine Gaming & Digital Entertainment VanEck Video Gaming and eSports ETF ( ESPO ) NetEase Interactive entertainment and online engagement Space Infrastructure VanEck Space ETF ( WARP ) Rocket Lab Launch, satellites, and orbital data Robotics & Automation VanEck Robotics ETF ( IBOT ) ABB Industrial automation, robotics, and electrification Semiconductors VanEck Semiconductor ETF ( SMH ) NVIDIA AI compute and chip infrastructure Click to enlarge 1. Gilead Sciences Inc. ( GILD ) ETF exposure: Top holding in BBH at 14.25% of net assets as of 05/21/2026. What They Do: Gilead Sciences is a global biopharmaceutical company with a portfolio spanning HIV, liver disease, oncology and inflammation. From a technology perspective, Gilead represents the life sciences side of innovation: using molecular biology, clinical data and advanced drug development to create therapies for complex diseases. 2026 Watch Point: The biotech opportunity is increasingly tied t...
AN2 Therapeutics ( ANTX ) added ~7% in the premarket on Thursday after posting results from two early-stage studies evaluating AN2-502998, its experimental therapy for a parasitic infection known as Chagas disease (American trypanosomiasis). The Menlo Park, California-based biopharma said that the results, including data from a Phase 1 trial, supported its decision to advance AN2-502998 into mid-s...
AN2 Therapeutics ( ANTX ) added ~7% in the premarket on Thursday after posting results from two early-stage studies evaluating AN2-502998, its experimental therapy for a parasitic infection known as Chagas disease (American trypanosomiasis). The Menlo Park, California-based biopharma said that the results, including data from a Phase 1 trial, supported its decision to advance AN2-502998 into mid-stage development for chronic Chagas disease caused by the parasite T. cruzi. Citing data from a Phase 1 first-in-human trial, the company noted that trial subjects well tolerated the experimental therapy. AN2-502998 is an oral therapy designed to inhibit CPSF3, an essential enzyme involved in messenger RNA processing of T. cruzi. AN2 Therapeutics ( ANTX ) also shared data from a preclinical trial, noting that AN2-502998 led to the complete elimination of T. cruzi in non-human primates over four months after completing the therapy. In the study, NHPs with naturally acquired chronic T. cruzi infection received 28-day AN2-502998 therapy at dose levels achievable in humans. “Together, these data support our goal of making AN2-502998 the first FDA-approved therapy for chronic Chagas disease in adults,” CEO Eric Easom added. Chagas disease is estimated to affect more than 300,000 Americans. The company expects to launch a Phase 2 proof-of-concept study for AN2- 502998 later this year. More on AN2 Therapeutics AN2 Therapeutics, Inc. (ANTX) Presents at Leerink Global Healthcare Conference 2026 Transcript AN2 Therapeutics GAAP EPS of -$0.29 misses by $0.06 Seeking Alpha’s Quant Rating on AN2 Therapeutics Historical earnings data for AN2 Therapeutics Financial information for AN2 Therapeutics
Pulp Fiction director writes in Sight and Sound that ‘since the pandemic … it seems almost impossible for a new movie to come out that I don’t pick to death’ Quentin Tarantino has criticised contemporary Hollywood, calling it “a flavourless sausage factory”. Writing in Sight and Sound magazine, Tarantino said that “since the pandemic … it seems almost impossible for a new movie to come out that I ...
Pulp Fiction director writes in Sight and Sound that ‘since the pandemic … it seems almost impossible for a new movie to come out that I don’t pick to death’ Quentin Tarantino has criticised contemporary Hollywood, calling it “a flavourless sausage factory”. Writing in Sight and Sound magazine, Tarantino said that “since the pandemic … it seems almost impossible for a new movie to come out that I don’t pick to death”. He added: “Flaws, implausibilities, audience pandering, miscast performers or just plain stupid shit usually torpedoes every new movie coming out of the flavourless sausage factory that used to call itself Hollywood.” Continue reading...
Magone/iStock via Getty Images In my previous coverage of Danone published in July 2025, I focused primarily on the company's margin recovery, portfolio simplification, and the early benefits of the Renew Danone strategy. Since then, the story has evolved. While operational improvement remains important, I believe the more relevant development today is Danone's growing exposure to higher-value nut...
Magone/iStock via Getty Images In my previous coverage of Danone published in July 2025, I focused primarily on the company's margin recovery, portfolio simplification, and the early benefits of the Renew Danone strategy. Since then, the story has evolved. While operational improvement remains important, I believe the more relevant development today is Danone's growing exposure to higher-value nutrition categories through acquisitions and portfolio repositioning. That shift is the primary reason I am revisiting the stock. Danone continues to be valued as a mature business in dairy and bottled water, but the focus on earnings generation has started to move towards nutrition-related businesses. The trend of volume-driven growth is back, the importance of Specialized Nutrition has increased, and the acquisitions made have taken Danone deeper into medical nutrition, gut health, and complete nutrition. The Business Quality: A Nutrition Platform Wrapped in a Dairy Label Danone S.A. ( DANOY ) is among the biggest food and beverage companies in the world, being a leader in essential dairy & plant-based products, waters, and specialized nutrition. Some of its well-known brands include Activia, Actimel, Alpro, Oikos, Silk, Evian, Volvic, Aptamil, Nutrilon, and Nutricia. From an outside view, this looks to be just a regular portfolio of consumer staples names. The truth, however, is somewhat deeper. The driver behind this assumption is the mix. While Danone remains a prominent dairy player with an additional water and baby formula presence, it is increasingly becoming a nutrition company, with dairy remaining on the visible side while sometimes being secondary to profits. Specialized Nutrition accounts for approximately one-third of sales, and its profitability is much higher than this number would suggest. Nutrition businesses operate in a different way compared to traditional consumer staples companies. Categories such as infant formula, adult medical nutrition, or specializ...
Zhongchao ( ZCMD ) on Thursday said it will effectuate a 1-for-31 share consolidation of the company's ordinary shares of US$0.008 par value each. Beginning with the opening of trading on June 8, the company's Class A ordinary shares will begin trading on a post-share consolidation basis on Nasdaq under the same symbol "ZCMD." The objective of the share consolidation is to maintain its listing on ...
Zhongchao ( ZCMD ) on Thursday said it will effectuate a 1-for-31 share consolidation of the company's ordinary shares of US$0.008 par value each. Beginning with the opening of trading on June 8, the company's Class A ordinary shares will begin trading on a post-share consolidation basis on Nasdaq under the same symbol "ZCMD." The objective of the share consolidation is to maintain its listing on the Nasdaq Capital Market, the company said. Press release More on Zhongchao Financial information for Zhongchao